Ozempic, Wegovy & GLP-1 Vision Loss Lawsuit (NAION)

GLP-1 Vision Loss Lawsuit: Ozempic, Wegovy & Mounjaro NAION Claims

Our attorneys are actively reviewing GLP-1 vision loss lawsuits nationwide for people diagnosed with NAION (non-arteritic anterior ischemic optic neuropathy) after taking semaglutide or tirzepatide medications, including Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound.

If you or a loved one experienced sudden or permanent vision loss, blindness, or optic nerve damage after using one of these drugs, you may be eligible to file an Ozempic lawsuit or other GLP-1 claim and seek compensation for medical bills, lost income, and pain and suffering. Contact us today for a free, confidential case review.

Does Ozempic Cause Vision Loss?

A growing body of medical evidence suggests the answer may be yes—under certain conditions.

Recent studies, adverse event data, and ongoing litigation indicate a potential connection between ozempic and vision loss, particularly a condition known as:

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

What Is NAION (Semaglutide-Related Vision Loss)?

NAION (non-arteritic anterior ischemic optic neuropathy) is a serious eye condition caused by reduced blood flow to the optic nerve.

When this occurs:

• The optic nerve becomes damaged or dies
• Vision loss is often sudden and painless
• Damage is typically permanent and irreversible

Common Symptoms of NAION:

• Blurry or dim vision, often upon waking
• Shadow or dark spot in one eye
• Loss of color or contrast sensitivity
• Partial or complete vision loss

There is currently no effective treatment or cure for NAION.

Semaglutide and NAION: What the Research Shows

Key findings include:

• A 2024 Scandinavian cohort study (424,000+ patients) found semaglutide users had more than double the risk of developing NAION compared to other diabetes medications
• A meta-analysis of GLP-1 trials found a higher incidence of optic nerve injury in treatment groups
• FDA adverse event data suggests semaglutide-specific risk signals, not just GLP-1 drugs broadly

Wegovy May Carry Higher Risk

Despite sharing the same active ingredient as Ozempic, Wegovy (higher-dose semaglutide) has been linked to:

• Up to 5x increased risk of optic nerve injury
• Stronger safety signals in adverse event reporting

This has led to a surge in lawsuits against Wegovy.

Contact Us Today for a FREE Consultation

If you or a loved one has been injured due to the use of Ozempic, Wegovy, Rybelsus or any other brand name weight loss drugs, don’t wait to seek legal help.

Contact Salenger, Sack, Kimmel & Bavaro today for a FREE consultation.

Call (800) 675-8556 or contact us online to get started. 

Latest Developments in GLP-1 Vision Loss (NAION) Litigation (October 2026)

Federal MDL Continues to Grow
The federal multidistrict litigation (MDL) now includes more than 200 active cases, with hundreds of additional individual and state-court filings, including consolidated actions in New Jersey state court.

Science and Discovery Phase
In June 2026, the court held a “Science Day” to review medical and observational data on the alleged link between GLP-1 medications and non-arteritic anterior ischemic optic neuropathy (NAION). The litigation remains in active discovery and pretrial coordination through late 2026.

Regulatory Landscape

United States: The FDA has not yet formally required that NAION be added to GLP-1 drug labels. Drugmakers deny the claims and point to mixed or unproven evidence of a direct causal link.

International: Regulators in Europe (EMA), Canada, the United Kingdom, and Australia have acknowledged the potential rare risk of NAION on semaglutide labels or required warnings addressing it.

“Bootleg” GLP-1 Crackdowns

States have begun pursuing enforcement actions against unauthorized sellers of compounded or counterfeit GLP-1 drugs. In 2026, Connecticut reached a settlement with an international platform accused of selling unapproved “bootleg” GLP-1 medications.

Insurance Coverage Rulings

In May 2026, a Washington state appeals court ruled that insurance providers cannot impose blanket exclusions on GLP-1 medications prescribed for weight loss purposes, marking a significant legal development for patient access.

Medicare Pricing Changes

Beginning July 1, 2026, Medicare is expected to implement a program capping certain GLP-1 prescription costs at $50 per month for eligible beneficiaries. Increased access to these medications may further increase public scrutiny and litigation attention surrounding their alleged risks.

Ozempic & Wegovy Lawsuits: Legal Claims

Plaintiffs in ozempic lawsuits and wegovy class action lawsuits generally allege:

• Failure to warn about risk of blindness or optic nerve damage
• Defective drug design or inadequate safety testing
• Misrepresentation of safety in marketing
• Negligence in post-market surveillance

Many cases involve individuals who took the medication as prescribed and still developed NAION.

Who Qualifies for a Weight Loss Drug Lawsuit?

You may be eligible to file a weight loss drug lawsuit if:

• You took Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound
• You developed NAION or unexplained vision loss
• You sought treatment from a doctor, ophthalmologist, or neurologist
• You have supporting medical and prescription records

Required Documentation for Your Claim

To pursue an ozempic blindness lawsuit or wegovy lawsuit, you will need:

• Pharmacy records confirming use of semaglutide or tirzepatide
• Medical records diagnosing NAION or vision impairment
• Imaging or ophthalmology evaluations
• Documentation of lost income or lifestyle impact

Ozempic Lawsuit Settlement Amounts

While ozempic lawsuit settlement amounts are still developing, compensation in similar pharmaceutical cases has included:

• Medical expenses (past and future)
• Lost wages and diminished earning capacity
• Pain and suffering
• Emotional distress
• Permanent disability or blindness-related costs

Settlement values will depend on severity of injury, documentation, and long-term impact.

Time Limits to File (Statute of Limitations)

Time is limited. Most states have a 2-3 year statute of limitations from the date the injury occurred—or the date you discovered the link to your medication. In New York, the deadline is typically three years, but certain exceptions may apply.

We strongly encourage you to act now to protect your right to sue.

Why Work with Salenger, Sack, Kimmel & Bavaro?

With over four decades of experience in mass tort and product liability litigation, our firm is uniquely positioned to:

• Fight back against major pharmaceutical companies

• Provide personalized legal support at every step

• Work on a contingency-fee basis — you pay nothing unless we win

• Partner with renowned medical experts to strengthen your case

Contact a Weight Loss Drug Lawyer Today

If you suffered NAION, blurry vision, or blindness after using Ozempic, Wegovy, Rybelsus, Mounjaro, Victoza, or Saxenda, we’re here to help.

📞 Call 800-675-8556 for a free case evaluation
🖊 Or complete our confidential contact form today.